SLS · SELLAS Life Sciences Group, Inc. · Stock research

Current Thesis

The price driver is short-covering and M&A speculation; no new REGAL clinical data has been released. Shares have run from the mid-$8s (Jun 22) to a $16 resistance test (Jul 8) and settled near $13.04 (Jul 17, +10.9% on an Alliance Global price-target hike to $25 from $10). The leg rides record short interest 63.36M shares, ~32.4% of float, a ~9.25-day cover ratio plus buyout chatter seeded by change-of-control severance amendments. The event that actually re-rates the equity, the Phase 3 REGAL overall-survival readout in galinpepimut-S (GPS), has been stuck at 78 of 80 required death events since May 11 and remains blinded. Buying a squeeze into an undated, still-blinded OS coin-flip at +140% YTD is lottery gamma at peak premium a name to track for a post-data base, with the binary itself sitting outside the momentum edge.

Bullish and bearish views on SELLAS Life Sciences Group, Inc.

The model's bull view on SELLAS Life Sciences Group, Inc. (SLS), in brief: Sell-side is now chasing the tape: Alliance Global raised its PT to $25 from $10 and reaffirmed Buy (Jul 17), reframing the slow accumulation of REGAL death events as a survival-benefit tell rather than a delay. The bear view: The defining event is a binary OS analysis still blinded more than two months after reaching 78/80 (May 11); a hazard ratio that misses significance gaps the stock -50%+ with no fundamental floor, and the run to +140% YTD has priced a favorable outcome. Both cases follow in full.

Bull Case

• Sell-side is now chasing the tape: Alliance Global raised its PT to $25 from $10 and reaffirmed Buy (Jul 17), reframing the slow accumulation of REGAL death events as a survival-benefit tell rather than a delay.
• The IDMC unanimously recommended continuing REGAL without modification after an unblinded review of efficacy, futility, and safety the last committee to see the real data did not stop for futility.
• REGAL sat at 78/80 events as of May 11; final OS analysis triggers on two more deaths, so topline can print any session, and a significant hazard ratio re-rates the equity violently.
• Squeeze fuel is structural: short interest hit a record ~32.4% of float (63.36M shares) with a ~9.25-day cover ratio at ~6.85M average daily volume; the stock printed +10.9% to $13.04 on Jul 17 and tested $16 on Jul 8.
• Funded through the event: $107.1M cash at Mar 31 2026 plus ~$28.7M of warrant-exercise proceeds in Apr–May (Jun 2 8-K), minimal debt no forced raise required to reach the readout.
• Optionality beyond GPS: SLS009 (tambiciclib, CDK9 inhibitor) has Phase 2 first-line AML topline guided to ~Q4 2026.

Bear Case

• The defining event is a binary OS analysis still blinded more than two months after reaching 78/80 (May 11); a hazard ratio that misses significance gaps the stock -50%+ with no fundamental floor, and the run to +140% YTD has priced a favorable outcome.
• The bull reframe is contested: a Jul 2026 Seeking Alpha piece argues REGAL's delayed events reflect selection bias rather than a survival benefit the "slow deaths are good" read is a statistical guess on blinded data.
• The Jun 25–26 and Jul 17 pops traced to positioning and analyst commentary; no clinical data event drove any leg of the move, and the $16 rejection on Jul 8 shows supply arriving at round-number resistance.
• Dilution stacks into strength: the Jun 16 meeting approved +20M shares to the 2023 Equity Incentive Plan (42.9M for / 27.3M against), the CEO was granted 1.065M RSUs, and the $150M TD Cowen ATM on the S-3ASR shelf remains live against ~196.6M shares out.
• Single-asset concentration a failed REGAL strands GPS and pins the equity on SLS009, still years from any approval.
• The change-of-control severance amendments are as consistent with executives locking in payouts ahead of a binary as with an actual deal; the buyout read is unfalsifiable while the trial is blinded.

Setup & Price Structure

• Last ~$13.04 (Jul 17, +10.9%), off a $16 resistance test on Jul 8 that failed ("Shares Slip Wednesday as Price Tests $16 Resistance Wall").
• Leg structure: mid-$8s (Jun 22) → $10.33 (Jun 25) → ~$12.07 (Jun 26) → ~$16 (Jul 8) → pullback and re-pop to $13.04 (Jul 17).
• Price sits well above the entire prior $1.39–$9.51 range; the $9–$10 zone is the June launch shelf of the whole move.
• RSI has run hot on every leg since May (the 80s+ prints that preceded each pullback); the failed $16 test marks the first clear rejection of the run.
• Character: a squeeze staircase of higher lows on strong closes, but pullbacks are getting sharper as the level rises distribution into strength ahead of a blinded print.

Catalyst Calendar (next 30 days)

• Phase 3 REGAL topline (galinpepimut-S OS): event-driven at the 80th death; 78/80 as of May 11 can land any session, no fixed date. This is the binary and must not be assigned a calendar date.
• 3D Medicines arbitration ruling (~$13M): expected window early Jul–early Sep 2026; immaterial versus the ~$2B cap.
• Q2 2026 earnings: estimated ~mid-Aug 2026 (Q1 reported May 12); a non-driver here and possibly just outside the 30-day window.
• SLS009 (tambiciclib) Phase 2 first-line AML topline: guided ~Q4 2026 outside this window.

What Would Change Our Mind

• A clean REGAL topline with a statistically significant OS hazard ratio converts this from a positioning trade into a fundamental re-rate that is the post-data base worth waiting for.
• A weekly close below $10.00 loses the June squeeze staircase and signals short-covering exhaustion, confirming the leg was a positioning trade that has run its course.
• A confirmed buyout or definitive agreement not merely severance amendments would validate the M&A leg and remove the blinded-binary risk.
• A REGAL miss removes the entire thesis and re-rates the equity toward a cash-plus-SLS009 stub.

Correlation Notes

• Idiosyncratic single-name event risk: SLS trades on the REGAL binary and its short-squeeze mechanics rather than on the biotech tape or XBI beta index moves are noise against a coin-flip OS print.
• Squeeze cohort: behavior rhymes with other high-short-interest small-cap biotechs (the May 20 tape grouped SLS with IMVT, ROIV and other movers), but the shared factor is float mechanics high short interest, thin borrow not any common clinical driver.
• Rate/macro sensitivity is secondary: a clinical-stage, revenue-less, cash-funded name is driven by its own catalyst, and any correlation to peers collapses the moment topline prints.